DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

Vision - Slow the progression of, prevent, and cure Parkinson's disease in order to lessen personal and societal impact of the disorder

Parkinson's Research Program Cover Image
The Parkinson's Research Program (PRP) began in 1997. Projects examine neurodegenerative mechanisms and compensatory effects that compromise motor, autonomic and cognitive systems which are characteristic alterations in Parkinson's disease (PD) patients and which also present performance and health risks for military personnel.

The overall goals of the program are: 1) Develop means to correlate risk factors and dysfunction associated with PD, 2) Develop means to identify risk factors for subsets of the affected population, 3) Correlate clinical phenotype and molecular underpinning and 4) Develop candidate therapeutics, based on identified molecular pathway intervention points, to halt progression and extend quality of life for the at-risk population.

The program develops means to ameliorate the effect of risk factors by: 1) preventing or delaying development of the cardinal motor signs of the condition that compromise performance and long-term health and 2) identification of preventions and therapeutics for currently diagnosed patients. Specific risk factors of interest are: chemical exposures, prolonged physiological stress, depression, traumatic injury to the head, disordered sleep architecture and dysautonomia.

Congressional Appropriations

Congressional Appropriations

  • $404.75 million
    FY97-16
  • $16 million
    FY17

Funding Summary

Funding
Summary

...

Peer Review Participants


Related Videos

Dr. Kenneth Marek Video

Institute for Neurodegenerative Disorders
Evaluating the Natural History of Prodromal PD in the PARS Cohort

Dr. Caroline Tanner

University of California, San Francisco
Persistent Organic Pollutants and Parkinson’s disease in Native Populations of Hawaii and Alaska

Dr. Paul Greengard

Rockefeller University
New P11 Biomarker Predicts Clinical Effectiveness of Antidepressant Drugs

Dr. Howard J. Federoff

University of California, Irvine
PGC-1α Therapy for Parkinson Neurodegeneration

news_icon News & Highlights

Vision

Slow the progression of, prevent, and cure Parkinson's disease in order to lessen personal and societal impact of the disorder.

Mission

Identify surrogate markers of the disease, correlate distinctive clinical features with specific clusters of these markers, and develop interventions in bimolecular pathways that link markers and expressed clinical features.


Last updated Wednesday, June 14, 2017